- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Trial completion date, Trial primary completion date: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Feb 8, 2023 P2, N=60, Recruiting, ClinicalTrials.gov Identifier: NCT03670953. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Parkinson’s Disease Patient Characteristics in a US Real-World Study of Opicapone () - Oct 17, 2022 - Abstract #ANA2022ANA_605; While the study was conducted during the ongoing pandemic and investigators could initiate treatment via telemedicine, most investigators elected to initiate patients on opicapone with an in-person visit. Findings from OPTI-ON will further characterize the PD population treated with opicapone and real-world clinician- and patient-reported outcomes data in the US will complement results from previous controlled clinical trials.
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Learning and predicting Levodopa regimens from wearable sensors: A novel machine learning approach () - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1532; Our wearable-based RL policies suggest that the original n=26 study patients would experience lower bradykinesia (and unchanged dyskinesia) if switched to controlled-release L-dopa formulations such as Rytary... We show that pairing machine learning with even small quantities of wearable movement tracker data can offer novel, generalizable clinical insights and medication strategies, which can be used to improve care for other PD patients for whom wearable data are not available.
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Reimbursement, Journal, Medicare: Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i. (Pubmed Central) - May 7, 2022 In the state of Hawai'i, there is an urban-rural access gap to neurologists as evidenced by Medicare prescription pattern. Further study is needed to understand the reasons for rural-urban differences in prescription patterns and their impact on outcomes.
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Journal: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). (Pubmed Central) - Nov 24, 2021 Further study is needed to understand the reasons for rural-urban differences in prescription patterns and their impact on outcomes. In the ADVANCE-PD trial, CD-LD ER significantly increased ON time per dose compared to CD-LD IR (+1.21 h, p < 0.0001) and provided significantly more ON time per dose (3.55 h vs 2.38 h, p < 0.0001).
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Enrollment open: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Nov 18, 2021 P2, N=60, Recruiting, In the ADVANCE-PD trial, CD-LD ER significantly increased ON time per dose compared to CD-LD IR (+1.21 h, p < 0.0001) and provided significantly more ON time per dose (3.55 h vs 2.38 h, p < 0.0001). Not yet recruiting --> Recruiting
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Impax
Clinical, Journal: Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. (Pubmed Central) - Sep 4, 2019 IPX066 may also improve the patient´s compliance due to its simplified drug regimen. The marketing of IPX066 outside the US is complex since in countries like Germany, health-care payers only consider innovation in terms of mode of action whereas innovation of pharmacokinetic and pharmacodynamic properties is disregarded.
- |||||||||| Inbrija (levodopa inhalation powder) / Acorda
Journal: Inhaled levodopa (Inbrija) for Parkinson's disease. (Pubmed Central) - Aug 6, 2019 The marketing of IPX066 outside the US is complex since in countries like Germany, health-care payers only consider innovation in terms of mode of action whereas innovation of pharmacokinetic and pharmacodynamic properties is disregarded. No abstract available
|